Langenbeck's Archives of Surgery

, Volume 395, Issue 2, pp 185–192 | Cite as

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor

  • Oliver Stoeltzing
  • Martin Loss
  • Elisabeth Huber
  • Volker Gross
  • Christoph Eilles
  • Jan Mueller-Brand
  • Hans J. Schlitt
Case Management and Clinical Consequences



Treatment with DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), labeled with beta-emitting radioisotope yttrium-90 (90Y-DOTATOC), has successfully been used for the palliative treatment of patients with advanced somatostatin receptor-expressing neuroendocrine tumors (NETs). However, controversy persists as to whether patients with metastatic NETs of the pancreas should undergo radical (salvage) surgery or receive palliative therapy. We proposed that 90Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases.

Materials and methods

We investigated a novel therapy concept in a 49-year-old patient presenting with a neuroendocrine tumor of the pancreatic tail and synchronous multiple bilobular hepatic metastases. After surgical removal of the large primary tumor by extended left en bloc resection of the pancreatic tail, the patient received neoadjuvant 90Y-DOTATOC for therapy of primarily non-resectable bilobular hepatic metastases.


The 90Y-DOTATOC therapy resulted in an impressive regression of hepatic lesions, thus facilitating surgical removal of all remaining liver metastases in a second operation (staged surgery). In addition, one lesion was ablated using radiofrequency ablation (RFA). At 1-year of follow-up after hepatic R0 resection/RFA, there was no evidence of tumor recurrence or extrahepatic metastasis.


The neoadjuvant use of 90Y-DOTATOC therapy could prove valuable for treatment of advanced pancreatic NETs metastatic to the liver in terms of facilitating R0 resection by applying staged surgery concepts.


Liver resection Neoadjuvant therapy NET Pancreas Staged surgery 


  1. 1.
    Eckhauser FE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW (1986) Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 100(6):978–988PubMedGoogle Scholar
  2. 2.
    Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19(5):753–781. doi:10.1016/j.bpg.2005.06.002 PMID: 16253899CrossRefPubMedGoogle Scholar
  3. 3.
    Madura JA, Cummings OW, Wiebke EA, Broadie TA, Goulet RL Jr, Howard TJ (1997) Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 63(7):573–577 discussion 577-578. PMID: 9202529PubMedGoogle Scholar
  4. 4.
    de Herder WW, Krenning EP, Van Eijck CH, Lamberts SW (2004) Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr-Relat Cancer 11(1):19–34. doi:10.1677/erc.0.0110019 PMID: 15027883CrossRefPubMedGoogle Scholar
  5. 5.
    Carty SE, Jensen RT, Norton JA (1992) Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112(6):1024–1031 discussion 1031-1022. PMID: 1455305PubMedGoogle Scholar
  6. 6.
    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108(6):1091–1096 PMID: 1701060PubMedGoogle Scholar
  7. 7.
    Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival. Ann Surg 241(5):776–783. doi:10.1097/01.sla.0000161981.58631.ab discussion 783-775. PMID: 15849513CrossRefPubMedGoogle Scholar
  8. 8.
    Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Buchler MW (2008) Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 95(5):627–635. doi:10.1002/bjs.6051 PMID: 18306152CrossRefPubMedGoogle Scholar
  9. 9.
    Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244(6):845–851. doi:10.1097/01.sla.0000246951.21252.60 discussion 852-843. PMID: 17122609CrossRefPubMedGoogle Scholar
  10. 10.
    Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O (2004) Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 28(12):1248–1260. doi:10.1007/s00268-004-7609-8 PMID: 15517487CrossRefPubMedGoogle Scholar
  11. 11.
    Lang H, Schlitt HJ, Schmidt H, Flemming P, Nashan B, Scheumann GF, Oldhafer KJ, Manns MP, Raab R (1999) Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas—a single center experience with ten patients. Langenbecks Arch Surg 384(4):370–377. doi:10.1007/s004230050216 PMID: 10473858CrossRefPubMedGoogle Scholar
  12. 12.
    Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR (2007) Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB Oxf 9(5):345–351. doi:10.1080/13651820701504199 PMID: 18345317CrossRefGoogle Scholar
  13. 13.
    Forrer F, Waldherr C, Maecke HR, Mueller-Brand J (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26(1B):703–707 PMID: 16739341PubMedGoogle Scholar
  14. 14.
    Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43(5):610–616 PMID: 11994522PubMedGoogle Scholar
  15. 15.
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26(11):1439–1447. doi:10.1007/s002590050476 PMID: 10552085CrossRefPubMedGoogle Scholar
  16. 16.
    Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE (2006) Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140(6):968–976. doi:10.1016/j.surg.2006.07.030 discussion 976-967. PMID: 17188146CrossRefPubMedGoogle Scholar
  17. 17.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016. doi:10.1016/S0140-6736(08)60455-9 PMID: 18358928CrossRefPubMedGoogle Scholar
  18. 18.
    Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J (2005) Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 46(8):1310–1316 PMID: 16085587PubMedGoogle Scholar
  19. 19.
    Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K (2004) Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45(7):1161–1167 PMID: 15235062PubMedGoogle Scholar
  20. 20.
    Sundin A, Garske U, Orlefors H (2007) Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21(1):69–85. doi:10.1016/j.beem.2006.12.003 PMID: 17382266CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Oliver Stoeltzing
    • 1
  • Martin Loss
    • 1
  • Elisabeth Huber
    • 2
  • Volker Gross
    • 3
  • Christoph Eilles
    • 4
  • Jan Mueller-Brand
    • 5
  • Hans J. Schlitt
    • 1
  1. 1.Departments of Surgery and Surgical OncologyUniversity of Regensburg Medical CenterRegensburgGermany
  2. 2.Institute of PathologyUniversity of Regensburg Medical CenterRegensburgGermany
  3. 3.Department of Internal Medicine IISt. Marien Hospital AmbergAmbergGermany
  4. 4.Institute of Nuclear MedicineUniversity of Regensburg Medical CenterRegensburgGermany
  5. 5.Institute of Nuclear MedicineUniversity Hospital of BaselBaselSwitzerland

Personalised recommendations